• Adoption of all the resolutions presented in line with the recommendations of the Board of Directors
• Implementation of separation of powers:
o Thibaut du Fayet was appointed as Chief Executive Officer
o Didier Hoch will continue to act as Chairman of the Board of Directors
Nantes, December 15, 2022 – 6 p.m. CET – Pherecydes Pharma (FR0011651694 – ALPHE, PEA-PME eligible), a biotechnology company specializing in precision phage therapy intended to treat antibiotic-resistant and/or complicated bacterial infections, announces that the Combined General Meeting (AGM) of December 15, 2022 was able to validly deliberate, the quorum having been reached.
To receive all of Pherecydes Pharma’s financial information in real time, send a request by email to [email protected]. Your registration will be immediate.